AEBi Overview
Accelerated Evolution Biotechnologies (AEBi) is a development-stage biopharmaceutical company engaged in the discovery and development of therapeutic peptides. The company has developed an IP-protected combinatorial biology screening platform technology that can be used to find binders to known targets and select the best functional molecules among them. AEBis platform is extremely flexible, harnessing combinatorial biology to discover new and better lead compounds to disease targets. AEBi was incorporated at the Weizmann Institutes ITEK technological incubator in Nes-Tziona, Israel. The company has a collaboration agreement with Israeli biopharmaceutical company Proteologics.
Latest News
growth-positive
Israeli cancer treatment could be something special
Israeli company Accelerated Evolution Biotechnologies Ltd (AEB) claims to have developed a cure for all kinds of cancer. The treatment, called MuTaTo, is described as a multi-target toxin that specifically targets cancer cells. AEB has conducted successful experiments on mice and completed several in-vitro trials. They plan to start clinical trials within a few years. However, international experts have reacted skeptically to the claim, pointing out that the tests have only been done on mice and no results have been published in scientific journals. They believe it will take many more years before the treatment is widely available. Despite the skepticism, the author expresses hope that AEBs approach may be something special.
InvestmentPartnersCustomers
growth-negative
'Cancer cure' doubted as Israeli team claims it can't afford to publish findings
Israeli startup Accelerated Evolution Biotechnologies claims to have developed a concept that will lead to a cure for cancer. However, foreign cancer specialists have criticized the claims, with one US expert dismissing it as another false promise for cancer patients. The company has not published its research in medical journals due to financial constraints but claims that its pre-clinical trials have been successful. The treatment, called MuTaTo, is a personalized medication that targets multiple proteins expressed by cancer cells. The company hopes to begin clinical trials in a years time if it raises the necessary funds. Funding to date has come from private investors. The team aims to advance its research and get to clinical trials as quickly as possible.
InvestmentExpand
growth-negative
An Israeli Company Claims That They Will Have A Cure For Cancer In A Year. Don't Believe Them.
Israeli biotech company AEBi claims to have a cure for cancer within a year, but the claims are unsubstantiated and lack evidence. The companys CEO, Ilan Morad, states that they attack cancer receptors three at a time, which is categorically untrue. The companys website lacks scientific publications to support their claims. Cancer researchers and experts are skeptical of the companys approach, as there are over 200 different types of cancer, each with multiple subtypes. The claims have drawn international condemnation from cancer organizations, and the American Cancer Society states that similar breakthrough technologies have failed in the past. The coverage of the claims erodes trust in health journalists and researchers.
CustomersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | aebi-bio.com |
Locations
Einstein St 13, Ness Ziona, Israel
Photos & Videos
No files yet
AEBi Business
Business models
B2B
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesTags (9)
drug-developmentdrug-discoverybiopharmaceuticalpharma-companiespatent-pendingscreeningpharmaceuticalspersonalized-medicinecancerGeographic Markets
IsraelAEBi Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Pre-Funding
Funding stage
0
Total rounds
0
Investors
AEBi Lifecycle
AEBi News
3 articles
growth-positive
Israeli cancer treatment could be something special
Israeli company Accelerated Evolution Biotechnologies Ltd (AEB) claims to have developed a cure for all kinds of cancer. The treatment, called MuTaTo, is described as a multi-target toxin that specifically targets cancer cells. AEB has conducted successful experiments on mice and completed several in-vitro trials. They plan to start clinical trials within a few years. However, international experts have reacted skeptically to the claim, pointing out that the tests have only been done on mice and no results have been published in scientific journals. They believe it will take many more years before the treatment is widely available. Despite the skepticism, the author expresses hope that AEBs approach may be something special.
InvestmentPartnersCustomers
growth-negative
'Cancer cure' doubted as Israeli team claims it can't afford to publish findings
Israeli startup Accelerated Evolution Biotechnologies claims to have developed a concept that will lead to a cure for cancer. However, foreign cancer specialists have criticized the claims, with one US expert dismissing it as another false promise for cancer patients. The company has not published its research in medical journals due to financial constraints but claims that its pre-clinical trials have been successful. The treatment, called MuTaTo, is a personalized medication that targets multiple proteins expressed by cancer cells. The company hopes to begin clinical trials in a years time if it raises the necessary funds. Funding to date has come from private investors. The team aims to advance its research and get to clinical trials as quickly as possible.
InvestmentExpand
growth-negative
An Israeli Company Claims That They Will Have A Cure For Cancer In A Year. Don't Believe Them.
Israeli biotech company AEBi claims to have a cure for cancer within a year, but the claims are unsubstantiated and lack evidence. The companys CEO, Ilan Morad, states that they attack cancer receptors three at a time, which is categorically untrue. The companys website lacks scientific publications to support their claims. Cancer researchers and experts are skeptical of the companys approach, as there are over 200 different types of cancer, each with multiple subtypes. The claims have drawn international condemnation from cancer organizations, and the American Cancer Society states that similar breakthrough technologies have failed in the past. The coverage of the claims erodes trust in health journalists and researchers.
CustomersInvestment
AEBi Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 1 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
AEBi Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 96/100 |
| Missing | video or image, funding rounds, markets |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 512970054 |
| Crunchbase | aebi-accelerated-evolution-biotechnologies |
| Phone | +97289300997 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-02-28T00:00:00.000Z |
| Created | 2015-02-12T00:00:00.000Z |
| Claimed | Yes |